ZORYVE® (roflumilast) Topical Foam, 0.3%, for the Treatment of Seborrheic Dermatitis Launches in the United States
ARQTArcutis Biotherapeutics(ARQT) Newsfilter·2024-01-22 21:00

o o o First drug approved for seborrheic dermatitis with a new mechanism of action in over two decades available in pharmacies this week Effective, safe, and very well-tolerated steroid-free foam provides rapid disease clearance and significant reduction in itch Seborrheic dermatitis affects more than 10 million people in the United States Management will host conference call on Monday, January 22 at 1:30 pm PST/4:30 pm EST ¢ WESTLAKE VILLAGE, Calif., Jan. 22, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutic ...